Related Experiment Videos
Association between SGLT-2 inhibitor use and retinal microvascular parameters in patients with Type 2 diabetes
Serap Castur1, Mehmet Umut Capar2, Serdar Sahin2
1Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye.
Aims:
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are widely used in Type 2 Diabetes Mellitus (T2DM) and may have neuroprotective and microvascular benefits. This study investigated SGLT-2i therapy effects on retinal microvasculature using optical coherence tomography angiography (OCTA) in T2DM patients.
Materials And Methods:
This cross-sectional study included 100 T2DM patients (46 receiving SGLT-2i, 54 non-users). Patients underwent comprehensive evaluation, including OCTA. Central macular thickness (CMT), superficial capillary vascular density (SCVD), deep capillary vascular density (DCVD), and radial peripapillary capillary (RPC) density were measured. BMI and HbA1c were recorded.
Results:
The SGLT-2i group had significantly higher weight and BMI (p < 0.01). Visual acuity and CMT did not differ between groups. However, non-users exhibited significantly higher DCVD in the whole retina, parafovea, and perifovea, and higher SCVD in the perifovea (p < 0.05). RPC densities in the inferior nasal and superior temporal regions were significantly higher in non-users (p < 0.05).
Conclusion:
SGLT-2i users showed lower retinal vessel densities compared to non-users. Due to the cross-sectional design, causality cannot be established; these results do not prove SGLT-2i adversely affects retinal microvasculature. Rather, these are hypothesis-generating observations. Prospective longitudinal studies are needed to clarify whether these findings reflect actual treatment effects or underlying patient characteristics.
Related Concept Videos
Diabetic Retinopathy
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type II Diabetes II: Pathophysiology
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Type II Diabetes I: Introduction